The PARADIGM-HF trial demonstrated that ARNI significantly reduces the risk of heart failure-related hospitalization and mortality in patients with heart failure with reduced ejection fraction (HFrEF), showing superior clinical efficacy over conventional angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs) [1]. Here, ACE is linked to hydrops fetalis.